| Budget Amount *help |
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2017: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2016: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2015: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Outline of Final Research Achievements |
The present study aimed to investigate the protective effect of remote ischemic preconditioning (RIPC) against spinal cord ischemia (SCI) and reveal its mechanism by measuring the glutamate concentration using an in vivo microdialysis in the ventral horn of the spinal cord. RIPC by limb-ischemia attenuated the increase of glutamate concentration in n the ventral horn and the decrease of motor evoked potential (MEP) amplitude due to SCI, and improved the post-SCI motor function and histopathologic changes in the spinal cord. Additionally, even with RIPC conditions, pre-administration of NMDA receptor antagonist (MK-801) led to increase the glutamate concentration and decrease MEP amplitude, and also worsened neurologic and histopathologic outcomes. Our study revealed that RIPC could show a protective effect against SCI both in early and late phases, and that the NMDA receptor played an important role for this preventive effect.
|
